At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 27 enrolled
Drug / intervention
RO7297089drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Multicenter, Phase I Trial Evaluating The Safety And Pharmacokinetics Of Escalating Doses Of RO7297089 In Patients With Relapsed Or Refractory Multiple Myeloma
In Brief
A Phase 1 clinical trial evaluating RO7297089 for Refractory Multiple Myeloma and Relapsed Multiple Myeloma. Completed, enrolled 27 participants across 10 sites in 4 countries.
Detailed Summary
This is a first-in-human Phase I, open-label, multicenter, global, dose-escalation study designed to evaluate the safety, tolerability, and pharmacokinetics of RO7297089 and make a preliminary assessment of anti-tumor activity in patients with R/R MM for whom no established therapy for MM is appropriate and available or who are intolerant to those established therapies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesAustralia, Belgium, Denmark, Norway
Collaborators--
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionFeb 2022
TodayJul 2026
First PostedJun 16, 2020
Enrollment StartJul 8, 2020
Primary CompletionFeb 23, 2022
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 6.0 years ago
Interventions
RO7297089drug
RO7297089 will be given via intravenous (IV) infusion